Lebin Jacob A, Mitchell Kaitlin, Trinkley Katy E, Calcaterra Susan L, Lun Zhixin, Hensen Colin, Hoppe Jason A
Department of Emergency Medicine, University of Colorado, Aurora, CO, USA.
Adult and Child Center for Outcomes Research and Delivery Science Center, University of Colorado, Aurora, CO, USA.
J Gen Intern Med. 2025 Jul 28. doi: 10.1007/s11606-025-09772-4.
Co-prescribing naloxone alongside opioid prescriptions reduces fatal opioid overdose risk in patients discharged from inpatient care, yet its adoption remains limited. Clinical decision support (CDS) tools are effective in increasing naloxone co-prescribing in emergency and primary care settings, but data from the inpatient setting is sparse.
To evaluate the effectiveness of an electronic health record (EHR)-integrated CDS tool on rates of naloxone co-prescribing for patients discharged from inpatient care with high-risk opioid prescriptions.
This observational, pre-post study evaluated an EHR-embedded CDS tool implemented within an integrated health system between July 10, 2011, and July 15, 2023.
Adult patients discharged from inpatient care with opioid prescriptions that met the Centers for Disease Control and Prevention high-risk criteria for opioid prescribing.
A multidisciplinary team designed an interruptive CDS best practice alert to identify high-risk opioid prescriptions. The CDS offered prescribers a one-click option to add a naloxone co-prescription.
Outcomes are organized under the RE-AIM implementation science framework, with the primary outcome, Effectiveness, measured by the proportion of patients receiving a naloxone prescription. Secondary outcomes include patient Reach, clinician Adoption, and fidelity to Implementation. Bayesian structural time-series models were used to evaluate differences in outcomes.
During the study period, there were 355,465 inpatient discharges. In the post-intervention period, the CDS was triggered in 2.2% (7799/355,465) of all discharges and 6.36% (7799/122,643) of all discharge opioid prescriptions. Compared to the pre-implementation period, CDS was associated with a weekly increase in inpatient naloxone co-prescribing by 4.7 prescriptions per 100 opioid prescriptions (95% CI 4.3-5, p = 0.001).
Implementation of an EHR-embedded CDS was associated with increased naloxone co-prescribing for high-risk opioid prescriptions in the inpatient setting. This finding demonstrates the potential of targeted, interruptive CDS tools to enhance opioid safety efforts in the inpatient setting.
在开具阿片类药物处方时同时开具纳洛酮可降低住院治疗出院患者阿片类药物过量致死风险,但该做法的采用率仍然有限。临床决策支持(CDS)工具在增加急诊和初级保健环境中纳洛酮联合处方方面有效,但来自住院环境的数据较少。
评估电子健康记录(EHR)集成的CDS工具对开具高风险阿片类药物处方的住院治疗出院患者纳洛酮联合处方率的有效性。
这项观察性前后对照研究评估了2011年7月10日至2023年7月15日期间在一个综合医疗系统内实施的嵌入EHR的CDS工具。
从住院治疗出院且开具的阿片类药物处方符合疾病控制与预防中心阿片类药物处方高风险标准的成年患者。
一个多学科团队设计了一种中断式CDS最佳实践警报,以识别高风险阿片类药物处方。该CDS为开处方者提供了一个一键选项,用于添加纳洛酮联合处方。
结果按照RE-AIM实施科学框架进行组织,主要结果“有效性”通过接受纳洛酮处方的患者比例来衡量。次要结果包括患者覆盖范围、临床医生采用率和实施的保真度。使用贝叶斯结构时间序列模型来评估结果差异。
在研究期间,共有355465例住院患者出院。在干预后时期,CDS在所有出院病例的2.2%(7799/355465)以及所有出院阿片类药物处方的6.36%(7799/122643)中被触发。与实施前时期相比,CDS与住院患者纳洛酮联合处方量每周每100张阿片类药物处方增加4.7张相关(95%可信区间4.3 - 5,p = 0.001)。
在住院环境中,实施嵌入EHR的CDS与开具高风险阿片类药物处方时纳洛酮联合处方量增加相关。这一发现证明了有针对性的中断式CDS工具在加强住院环境中阿片类药物安全工作方面的潜力。